Compare KN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | MESO |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2013 | N/A |
| Metric | KN | MESO |
|---|---|---|
| Price | $27.54 | $16.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.33 | N/A |
| AVG Volume (30 Days) | ★ 668.2K | 166.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $593,200,000.00 | N/A |
| Revenue This Year | $7.93 | $633.98 |
| Revenue Next Year | $8.28 | $29.51 |
| P/E Ratio | $54.54 | ★ N/A |
| Revenue Growth | ★ 7.17 | N/A |
| 52 Week Low | $12.19 | $9.61 |
| 52 Week High | $27.73 | $21.50 |
| Indicator | KN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 68.35 | 44.84 |
| Support Level | $26.58 | $16.71 |
| Resistance Level | $27.57 | $17.30 |
| Average True Range (ATR) | 1.00 | 0.49 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 91.26 | 43.82 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.